The company's common stock is listed on the NASDAQ Stock Market under the symbol "ICAD".
Investor Presentation
To access a copy of the investor presentation, please see below.
Quick Links
Investor Relations
Media Inquiries
Featuring presentations by Key Opinion Leaders Per Hall, MD, PhD (Karolinska Institutet), Axel Gräwingholt, MD (Radiologie am Theater), Joshua A. Nepute, MD (Indiana University Health-Arnett), and Emily F. Conant, MD (University of Pennsylvania Perelman School of Medicine) who will discuss the current landscape for digital breast tomosynthesis (DBT) and the potential for iCAD's recently introduced ProFound AI Risk, the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation based solely on a screening mammogram.
Featuring presentations by Key Opinion Leaders (KOLs) Janie Grumley, MD, FACS (John Wayne Cancer Center), Té Vuong, MD, FRCP (McGill University & Jewish General Hospital), and Santosh Kesari, MD, PhD (John Wayne Cancer Center), who discuss the current treatment landscape and unmet medical need in treating patients with cancers such as breast, rectal, and glioblastoma multiforme. Also highlighted will be recently presented positive clinical data for Xoft® Brain IORT as viable treatment option for glioblastoma multiforme.
iCAD, Inc.
603.882.5200
pr@icadmed.com
iCAD is committed to corporate sustainability and to making a difference for our environment.
Recent Press Releases
January 6, 2021
iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
December 10, 2020
Solis Mammography Adopts iCAD’s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution
December 3, 2020
iCAD Hosting Investor Webinar on Expanded ProFound AI Portfolio with New Breast Cancer Risk Assessment Solution
November 30, 2020
iCAD Highlights Expanded Suite of Leading Breast Health AI Solutions at Virtual RSNA 2020
Recent Events and Webcasts
January 6-8 and 11-14, 20214:30 pm ET
iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
November 5, 20204:30 pm ET
iCAD To Report Third Quarter 2020 Financial Results
September 1-4, 202011:00 am ET - Track 4
iCAD to Present at the LD Micro 500 Virtual Conference
August 4, 20204:30 pm ET
iCAD to Report Second Quarter 2020 Financial Results on Tuesday, August 4
May 11, 20204:30 pm ET
iCAD to Report First Quarter 2020 Financial Results on Monday, May 11
Resources
Precise and Powerful Healthcare Solutions
© 2020, iCAD Inc. All rights reserved. iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.
iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The core business delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and while enhancing patient care. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection (CAD) and radiation therapy (eBx) treatments.